Drew concedes slow sales of homocysteine test:
This article was originally published in Clinica
Executive Summary
Keith Drew, chairman of Drew Scientific, a UK company which produces a homocysteine cardiac market diagnostic, says that despite a great deal of interest in the US for the product, sales during the summer have been slower than anticipated. The company says that strong demand for its core diabetes products mean that it expects to match last year's full-year sales of £3 million ($4.3 million) within the next six weeks.